Genexine Inc
095700
Company Profile
Business description
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.
Contact
700 Daewangpangyo-ro, Gyeonggi-do
Korea Bio Park Building B, Bundang-gu
Seongnam-si13488
KORT: +82 316283200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
89
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,723.50 | 17.90 | -0.20% |
| CAC 40 | 7,575.99 | 22.54 | 0.30% |
| DAX 40 | 23,326.60 | 269.22 | 1.17% |
| Dow JONES (US) | 42,317.15 | 145.49 | 0.34% |
| FTSE 100 | 8,774.44 | 17.36 | -0.20% |
| HKSE | 23,530.48 | 292.74 | 1.26% |
| NASDAQ | 19,484.80 | 61.47 | -0.31% |
| Nikkei 225 | 38,403.23 | 85.11 | -0.22% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,982.33 | 1.46 | 0.02% |
| S&P/ASX 200 | 8,505.50 | 18.20 | -0.21% |
| SSE Composite Index | 3,359.90 | 2.21 | -0.07% |